核受体PPARγ的激动剂可以产生偏差信号
Mariah L Rayl1, Michelle D Nemetchek1, Andrew H Voss1
1Biochemistry and Biophysics Graduate Program (M.L.R., T.S.H.), Department of Biomedical and Pharmaceutical Sciences (M.D.N., T.S.H.), and Pharmaceutical Sciences and Drug Design Graduate Program (A.H.V., T.S.H.), University of Montana, Missoula, Montana.
核受体激动剂,包括部分激动剂,通过优先招募协同激活剂,表现出偏向信号. 这种选择性联合激活剂的招募影响了转录结果,为开发向核受体药物提供了洞察力.
科学领域:
- 分子药理学分子药理学
- 内分泌学 在内分泌学.
- 基因组学就是基因组学.
背景情况:
- 核受体中偏差信号和连接体偏差是已知的现象.
- 部分激动剂信号差异背后的机制尚不清楚.
- 共激活器招募偏差是一种偏差信号的拟议机制.
研究的目的:
- 为了研究核受体中的偏差信号.
- 通过联合激活剂招募来确定部分激动剂是否表现出偏差信号.
- 为了比较不同激动剂在人类脂肪细胞中的转录效应.
主要方法:
- 评估了GW1929 (全激动剂) 和MRL24 (部分激动剂) 与罗西格利塔 (全激动剂) 的联合激活剂招募概况.
- 利用RNA测序和基因和基因组京都百科全书 (KEGG) 途径分析来比较人类脂肪细胞中的转录效应.
- 量化偏差值和对联合激活剂招募和基因表达变化的置信区间.
主要成果:
- 与罗西格利塔相比,GW1929和MRL24都有利于招募特定的S-动机联合激活器区域.
- GW1929和MRL24在受体上显示了较高的S-动机协活性剂占用率.
- 在激动剂之间观察到转录效应和KEGG通路调节的显著差异,即使是在以后的时间点.
结论:
- 核受体激动剂,无论是完全的还是部分的,都可以诱导偏差信号.
- 偏差信号可能通过差异性协活性剂招募发生.
- 这些发现支持了用于药物开发的核受体中偏向激进的概念.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
相关概念视频
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
GPCRs Regulate Adenylyl Cylase Activity
Amplifying Signals via Enzymatic Cascade
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
GPCR Desensitization
